Repurposing bosentan as an anticancer agent: EGFR/ERK/c‐Jun modulation inhibits NSCLC tumor growthMarwa M. Khalaf, Maha M. Abdel‐Fattah|Fundamental and Clinical Pharmacology|2025Cited by 3